IRCT20190315043060N1尚未招募早期 1 期
Investigation of Pramipexole’s possible efficacy to diminish liability to relapse of drugs of abuse: A double-blind randomized placebo-controlled study
试验速览
- 阶段
- 早期 1 期
- 状态
- 尚未招募
- 入组人数
- 100
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 18 years 至 65 years（—）
- 性别
- All
入选标准
- •1- Patients who have administered stimulants (i.g. methamphetamine) at least 2 days in the past month.
- •2- Patients who have negative urine analysis for other addictive substances or the history of co-administration of drugs of abuse for no less than 3 weeks ago
- •3- Patients who meet the criteria of DSM-V for substance use disorder.
- •4- Patients who have failed to reduce or abstain currently abused substance at least for 2 times.
- •5- Patients who are seeking treatment and willing to abstain.
- •6- Age between 18 to 65 years
- •7- Patients who provide written informed consent.
- •8- Patients who have interest and are able to take part in a 4-month treatment phase and a 3-month follow up phase study (overall of 7 months).
- •9- Patients are only allowed to use pain killers, drugs used for neuropathic pain (gabapentin or pregabaline), and sleep aids (only benzodiazepines and Z-drugs)
排除标准
- 未提供
研究者
相似试验
已完成
3 期
Pramipexole in Untreated and Levodopa-treated Parkinson's Disease PatientsParkinson DiseaseNCT02177357Boehringer Ingelheim150
已完成
不适用
Assessment of the Safety and Efficacy of Pramipexole Extended Release in Patients With Parkinson's Disease in Routine Clinical PracticeParkinson's DiseaseNCT01061567Boehringer Ingelheim1,814
进行中（未招募）
1 期
Safety and Efficacy of Pramipexole Treatment in Resistant Obsessive-Compulsive Disorder (OCD): Pilot, Randomized and Controlled Clinical TrialObsessive-compulsive disorder (OCD)MedDRA version: 20.0Level: LLTClassification code: 10030029Term: OCD Class: 10037175CTIS2024-511085-37-00CCAB Centro Clinico Academico Braga Associacao48
已完成
3 期
Randomized Single-blind Placebo Controlled Comparative Trial of Pramipexole and Bromocriptine in Parkinson's DiseaseParkinson DiseaseNCT00240409Boehringer Ingelheim208
已完成
2 期
Dose Finding Study of Pramipexole (Sifrol) in Patients With Idiopathic Restless Legs Syndrome (RLS)Restless Legs SyndromeNCT00239486Boehringer Ingelheim109